Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 45-56

  Zámečníkova, Adriana ^a  

^a KUWAIT CANCER CONTROL CENTER   (Kuwait)

Author keywords

Chronic myeloid leukemia; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BOSUTINIB; BUSULFAN; CHAPERONE; CYTOTOXIC AGENT; DASATINIB; GENISTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HERBIMYCIN A; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TROXACITABINE; TYRPHOSTIN;

CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EDEMA; ENZYME ACTIVITY; FLUID RETENTION; HUMAN; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; ONCOGENE; PATIENT COMPLIANCE; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; PROTO ONCOGENE; PROTO ONCOGENE BCR; RASH; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CHROMOSOMES, HUMAN; DRUG DESIGN; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 77953462904     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.66     Document Type: Review

References (77)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N. Eng. J. Med. 341, 164-172 (1999).
2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441-453 (2007).
3. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral center over a 16-year period. Br. J. Haematol. 96, 111-116 (1997).
4. Radich JP. The biology of CML blast crisis. Hematology 1, 384-391 (2007).
5. Rowley JD. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290-293 (1973).
6. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 132, 1497 (1960).
7. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464 (2003).
8. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375-2384 (1996).
9. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood 96, 3343-3356 (2000).
10. Bruno C, Danilo P. The biology of CML blast crisis. Blood 103, 4010-4022 (2004).
11. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113, 1619-1630 (2009).
12. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 112, 4808-4817 (2008).
13. Geary CG. The story of chronic myeloid leukaemia. Br. J. Haematol. 10, 2-11 (2000).
14. Gratwohl A, Brand R, Apperley J et al. Allogeneic hematopoietic stem cell transplant for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 91, 513-521 (2006).
15. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653 (2005).
16. Okabe M, Uehara Y, Miyagishima T et al. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth. Blood 80, 330-1338 (1992).
17. Anafi M, Gazit A, Zehavi A, Ben Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 82, 3524-3529 (1993).
18. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100-104 (1996).
19. Carroll M, Ohno Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90, 4947-4952 (1997).
20. Jabbour E, Cortes JE, Ghanem H, O'Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev. Anticancer Ther. 8(1), 99-110 (2008).
21. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
22. Kantarjian H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652 (2002).
23. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood 99, 1928-1937 (2002).
24. Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a Phase II study. Blood 99, 3530-3539 (2002). (Pubitemid 34534519)
25. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
26. Palandri F, Castagnetti F, Alimena G et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica 94, 205-212 (2009).
27. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113, 5401-5411 (2009).
28. Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111, 4022-4028 (2008).
29. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology 183-187 (2005).
30. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
31. Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475 (2002).
32. Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196 (2002).
33. Branford S, Rudzki Z, Walsh S et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
34. Ernst T, Erben P, Muller MC et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 93, 186-192 (2008).
35. Martinell GI, Soverini S, Iacobucci I. What we don't know about resistance to tyrosine kinase inhibitors in CML: what makes CML cells a tougher enemy than expected? Clin. Leukemia 2, 86-87 (2008).
36. Koptyra M, Falinski R, Nowicki MO et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108, 319-327 (2006).
37. Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J. Natl Cancer Inst. 99, 680-693 (2007).
38. Stoklosa T, Poplawski T, Koptyra M et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 68, 2576-2580 (2008).
39. Margret S, Rodrigues, Martin S. Chronic myelogenous leukemia progenitors display a genetically unstable personality. J. Natl Cancer Inst. 99, 662-663.
40. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104, 3739-3745 (2004).
41. White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110, 4064-4072 (2007).
42. Hiwase DK, Saunders V, Hewett D et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res. 14, 3881-3888 (2008).
43. White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697-704 (2006).
44. Zhang WW, Cortes JE, Yao H et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol. 27, 3642-3649 (2009).
45. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous Leukemia 357, 258-265 (2007).
46. Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood 109, 5143-5150 (2007). (Pubitemid 46890528)
47. Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66, 5790-5797 (2006).
48. O'Hare T, Eide CA, Deininger MW. BCR-ABL kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110, 2242-2249 (2007).
49. Redaelli S, Piazza R, Rostagno R et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J. Clin. Oncol. 27, 469-471 (2009).
50. Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92, 401-404 (2007).
51. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109, 2303-2309 (2007). (Pubitemid 46425867)
52. Guilhot F, Apperley JF, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109, 4143-4150 (2007). (Pubitemid 46743375)
53. Apperley JF, Cortes JE, Kim DW et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J. Clin. Oncol. 27, 3472-3479 (2009).
54. Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109, 3207-3213 (2007).
55. Shah NP, Kantarjian HM, Kim DW et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212 (2008).
56. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110, 3540-3546 (2007).
57. le Coutre P, Ottmann OG, Giles F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 15, 1834-1839 (2008).
58. Giles FJ, Larson RA, Kantarjian HM et al. Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib. Blood 110, 310a (2007).
59. Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of Bcr/Abl point mutations conferring resistance to the Abl kinase inhibitor AMN107 (Nilotinib) by a random mutagenesis study. Blood 109, 5011-5015 (2007).
60. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther. Clin. Risk Manag. 5, 281-289 (2009).
61. Castagnetti F, Palandri F, Gugliotta G, et al. Thyrosin kinase inhibitors: nilotinib. Hemat. Meeting Rep. 2, 22-26 (2008).
62. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 111, 2329-2338 (2008).
63. Gambacorti-Passerini C, Kantarjian HM, Baccarani M et al. Activity and tolerance of bosutinib in patients with AP and BP CML and Ph+ ALL. J. Clin. Oncol. 26s, 7049 (2008).
64. Martinelli G, Iacobucci I, Cilloni D, Giannoulia P, Soverini S, Piccaluga PP. New drugs to overcome mechanisms of resistance in Ph+ leukemia: bosutinib. Hemat. Meeting Reports 2, 27-32 (2008).
65. Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306, 277-280 (1983).
66. Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233, 212-214 (1986).
67. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079-1082 (1990).
68. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
69. Koschmieder S, Gottgens B, Zhang P et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334 (2005).
70. Cohen M, Johnson J, Pazdur R. U.S. food and drug administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin. Cancer Res. 11, 12-19 (2005).
71. Kantarjian H, Talpaz M, O'Brien S et al. Survival benefit with imatinib mesylate versus-interferon a-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 108, 1835-1840 (2006).
72. Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
73. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204-2205 (2004).
74. Rousselot P, Huguet F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58-60 (2007).
75. Mahon FX, Rea D, Guilhot F et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial. J. Clin. Oncol. 27, 7084 (2009).
76. Quintás-Cardama A, Kantarjian H, Jones D et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113, 6315-6321 (2009).
77. Palandri F, Iacobucci I, Soverini S et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin. Cancer Res. 15, 1059-1063 (2009).